Researchers led by Christopher P. Holstege, MD, director of UVA Health’s Blue Ridge Poison Center, examined reports submitted to U.S. poison centers from 2000 through 2024. When the data were adjusted for population growth, the rate of reported xenobiotic-related liver injury rose from 10.9 cases per million people to 52.9 cases per million. That represents an increase of almost 400 percent. The study does not mean that every liver injury in the country was captured, because poison center records reflect calls made by the public and health professionals rather than a complete national registry. However, poison centers are an important source of real-time toxicological surveillance, allowing scientists to detect changes in exposure patterns before they become visible in slower-moving health statistics.

More than 80 percent of the reported cases required inpatient medical care, suggesting that many of the exposures were clinically serious rather than minor or transient reactions. The liver is particularly vulnerable to toxic substances because it receives blood from the digestive tract and is responsible for chemically modifying, storing and eliminating a vast range of compounds. During this process, enzymes can convert an otherwise harmless substance into a reactive metabolite capable of damaging liver cells. Injury may begin with inflammation or cellular stress and progress to impaired bile flow, widespread hepatocyte death, acute liver failure and, in the most severe cases, the need for transplantation.

Medications accounted for the majority of the injuries recorded in the study, with acetaminophen emerging as the most frequently implicated substance. The drug is widely used to reduce pain and fever and is present in hundreds of prescription and nonprescription products. Under normal conditions, the liver safely processes most acetaminophen through chemical pathways that produce inactive compounds. A smaller fraction is converted into a reactive metabolite known as N-acetyl-p-benzoquinone imine, or NAPQI. The body normally neutralizes NAPQI with the antioxidant glutathione, but excessive doses can deplete glutathione and allow the metabolite to attack liver proteins and cellular structures.

The study found that liver injuries associated with acetaminophen-containing combination prescription products fell sharply—by approximately 60 to 85 percent—after the U.S. Food and Drug Administration limited the amount of acetaminophen permitted in those medicines. The decline suggests that regulatory action reduced the risk created by products that combined acetaminophen with other active ingredients, particularly when patients were unaware that multiple medicines contained the same pain reliever. At the same time, injuries linked to acetaminophen taken by itself increased steadily over the period studied. That pattern indicates that the drug remains a major source of toxic exposure even as one category of combination products has become safer.

Women had higher rates of acetaminophen-associated liver injury than men, while suspected suicide was the most common reason for exposure in both sexes. The data point to the importance of distinguishing accidental medication errors from intentional overdoses, because the medical response, prevention strategies and public health interventions differ substantially. Accidental exposure can occur when patients take several products with overlapping ingredients, misunderstand dosing instructions or use more than recommended while attempting to control severe pain or fever. Intentional ingestion requires rapid emergency assessment as well as mental health support. In either situation, early treatment is critical because symptoms may be mild or absent during the first stage of acetaminophen poisoning.

Alcohol was the second most common contributor to reported liver injuries, although it occurred far less frequently than acetaminophen-related cases. Alcohol-associated injuries were reported more often among men than women, but exposures increased in both groups during the COVID-19 pandemic. Alcohol can injure the liver through several overlapping mechanisms, including the accumulation of toxic metabolic products, oxidative stress, disruption of fat metabolism and activation of inflammatory pathways. Repeated heavy exposure can lead to fatty liver, alcoholic hepatitis and scarring, while a particularly large exposure or combination with other toxic substances may produce acute injury. The pandemic-era increase observed in poison center reports mirrors broader concerns about changes in alcohol consumption and substance use during periods of social disruption.

The researchers also documented rising reports involving stimulants, illicit drugs, herbal and dietary supplements and environmental toxins. These categories were less common than acetaminophen and alcohol, but they reflect a growing challenge for clinicians and poison specialists: the chemical landscape of consumer exposure is constantly changing. Supplements may contain concentrated botanical compounds, undisclosed pharmaceuticals or contaminants, and their formulations can vary between products and batches. Stimulants and street drugs may be mixed with other substances that increase toxicity, while environmental chemicals can affect the liver through metabolic activation or prolonged low-level exposure. Because many emerging products are not subject to the same premarket testing as approved medicines, identifying the exact substance and dose can be difficult during an emergency.

Holstege said the findings underscore the need for consumers to follow clinical advice and pharmaceutical label instructions, while exercising particular caution with unregulated or newly emerging substances. The results also demonstrate how poison centers can function as an early-warning system for public health. Their records can reveal shifts in drug-related harm, identify vulnerable populations and show whether a policy change is associated with a meaningful reduction in poisoning. Still, the study’s observational design cannot prove that every increase resulted from a single cause. Changes in calling behavior, awareness of poison center services, clinical recognition, product availability and patterns of intentional self-harm may all influence the numbers. Even with those limitations, the scale and persistence of the increase point to a widening need for medication safety education, clearer labeling, careful supplement oversight and rapid access to toxicology expertise.

UVA Health’s Blue Ridge Poison Center provides free, confidential guidance around the clock for suspected poison exposures, including medication overdoses and possible liver-toxic substances. The center can be reached in the United States at 1-800-222-1222. People should not wait for symptoms before seeking advice, particularly after a suspected acetaminophen overdose, because serious liver injury can develop while early warning signs remain subtle. The new study, published in Clinical Gastroenterology and Hepatology, was authored by Eleanor Blair Towers, Christopher P. Holstege, Scott Schmalzried and Rita Farah. The researchers reported that they had no financial interest in the work.

Subject of Research: People

Web References: https://makingofmedicine.virginia.edu/

References: Clinical Gastroenterology and Hepatology

Image Credits: UVA Health

Keywords: liver injury, acetaminophen, poisoning, xenobiotics, poison centers, medication safety, alcohol-related liver disease, dietary supplements, toxicology, UVA Health

The study examines the effects of grape seed extract nanoparticles on liver cells exposed to CCl₄, a well-known hepatotoxin that can cause significant liver injury. The researchers focused on the role of inflammatory cytokines, which are proteins released during the immune response, significant contributors to liver damage when overproduced. Elevated levels of these cytokines are often observed in conditions leading to inflammation and fibrosis in the liver, prompting the investigation into how these nanoparticles might modulate such responses.

By employing advanced extraction and nanoparticle creation techniques, the scientists were able to isolate the beneficial compounds found in grape seeds, which are rich in antioxidants and polyphenols. This extraction resulted in nanoparticles that not only preserved the integrity of the active compounds but also enhanced their bioavailability. This increased efficacy is critical, as it enables lower doses to achieve significant therapeutic effects while potentially minimizing side effects.

The experimental setup included exposing liver cells to CCl₄ before treating them with varying concentrations of grape seed extract nanoparticles. The results were compelling, with observed reductions in the production of several inflammatory cytokines that are typically elevated in liver injury scenarios. This finding provides a promising indication that these nanoparticles may help mitigate the inflammatory responses associated with hepatotoxicity.

Moreover, the investigation delved into the mechanisms through which these grape seed extract nanoparticles exert their protective effects. It was discovered that the nanoparticles downregulated the expression of pro-inflammatory cytokines, thus leading to a decrease in oxidative stress and an overall improvement in liver cell viability. This molecular understanding is crucial as it opens doors for further research that could improve the therapeutic use of such nanoparticles in clinical settings.

One of the study’s standout conclusions is the potential for grape seed derived nanoparticles to be developed into a safe and efficient alternative therapeutic modality. Given the increasing prevalence of liver diseases globally—often exacerbated by lifestyle factors and environmental toxins—these findings hold immense clinical significance. The translation of laboratory results into real-world applications could provide a much-needed defense against liver toxicity for at-risk populations.

It is noteworthy to mention the significance of using natural products such as grape seeds in the development of nanomedicines. The move toward utilizing biocompatible and biodegradable materials caters not only to efficacy but also to safety. This strategic direction aligns with the growing trend in medicine to favor treatments that harness the body’s natural processes rather than introducing synthetic chemicals that may lead to adverse side effects.

The study highlights the growing interest in the field of complementary and alternative medicine, particularly within the realm of managing chronic illnesses. By securing the beneficial components of natural extracts in a nanoparticle format, researchers can offer new hope for patients suffering from chronic liver disease, which often ends in severe complications if untreated.

In addition, the ability to manipulate the size and surface properties of nanoparticles enables tailored pharmaceutical interventions. This specificity is crucial for enhancing interaction with target cells and improving the overall therapeutic effect—an element that is often lacking in conventional treatments.

The findings presented by Madbouly and collaborators are a prime example of interdisciplinary collaboration, blending insights from biology, chemistry, and medicine to tackle significant health concerns. Their work exemplifies how innovation within scientific research can lead to breakthroughs that address unmet medical needs.

As the healthcare landscape continues to evolve with a strong focus on personalized medicine, the integration of nanotechnology and natural product research appears more pertinent than ever. Future studies will be vital in assessing the long-term effects and the potential for clinical application of these nanoparticles, ensuring that therapeutic strategies adapt to the ever-changing patterns of liver disease incidence.

In conclusion, the study’s promising results demonstrate that nanoparticles derived from grape seed extract can inhibit inflammatory processes and protect against CCl₄-induced hepatotoxicity. This research could potentially shift perspectives on how we approach liver health, suggesting that natural compounds—when technologically advanced—can serve as formidable allies in the fight against liver toxicity and associated diseases.

The implications of these findings extend beyond the immediate scope of liver health. They illustrate the broader potential of using naturally derived nanoparticles to address acute and chronic inflammatory conditions in various organ systems. As research progresses, we can anticipate further unveiling of the therapeutic potentials carried by natural products, which may contribute not only to enhanced medical treatments but also to a more holistic understanding of health and wellbeing.

Subject of Research: The effects of grape seed extract nanoparticles in inhibiting inflammatory cytokines and ameliorating CCl₄-induced hepatotoxicity.

Article Title: Nanoparticles from grape seed extract inhibit inflammatory cytokines and ameliorate CCl₄-induced hepatotoxicity.

Article References: Madbouly, N.A., Ali, D.M. & Farid, A.A. Nanoparticles from grape seed extract inhibit inflammatory cytokines and ameliorate CCl₄-induced hepatotoxicity. BMC Complement Med Ther 25, 276 (2025). https://doi.org/10.1186/s12906-025-05005-7

Image Credits: AI Generated

DOI: 10.1186/s12906-025-05005-7

Keywords: nanoparticle, grape seed extract, hepatotoxicity, inflammatory cytokines, liver health, nanotechnology, natural products, antioxidant, chronic liver disease, biocompatible, therapeutic strategies, personalized medicine.